HomeAI · summaries
Storia in 5 fonti
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast…
- ·
morningstar.com
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not…
